Back

Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort

1 September 2019 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: How good/bad are we in treating lipids Secondary Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Baris Gencer

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

6 More presentations in this session

Presentation thumbnail
Attributable risk proportion of uncontrolled low-density lipoprotein cholesterol in recurrent acute coronary syndromes
Doctor E. Martinez Rey-Ranal (Elche, ES)
Abstract Slides
Presentation thumbnail
Statin treatment in children with familial hypercholesterolemia in Scandinavia
Doctor K. Svendsen (Oslo, NO)
Abstract Slides
Presentation thumbnail
Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
Doctor E. Hagstrom (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES
Professor G. Schwartz (Aurora, US)
Abstract Slides
Presentation thumbnail
Remnant lipoprotein is a residual risk of future cardiovascular events in patients with stable coronary artery disease and on statin LDL-cholesterol levels less than 70 mg/dl
Doctor Y. Fujihara (Kofu, JP)
Abstract Slides

Access the full session

Session thumbnail
How good/bad are we in treating lipids

The Event

Event poster

ESC Congress 2019

1 September 2019 10:05 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources